Clinical Trials
512
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (315 trials with phase data)• Click on a phase to view related trials
EEG-TMS Intervening Against Postoperative Delirium
- Conditions
- Postoperative Delirium
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT07100197
- Locations
- 🇨🇳
Renji hosipical, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Independent Effects of Visceral Adipose Volume and Density on Patient Survival in Peritoneal Dialysis
- Conditions
- UremiaEnd Stage Renal Disease on Dialysis
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 358
- Registration Number
- NCT07086430
Etomidate Combined With Propofol Versus Propofol for Sedation in High-Altitude Patients During Gastroscopy: a Randomized Multicenter Clinical Trial
- Conditions
- Gastrointestinal Endoscopy
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 732
- Registration Number
- NCT07079176
REST4-AAA Registry
- Conditions
- Abdominal Aortic Aneurysm
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT07056491
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
The Effectiveness of a TTM-based Multidisciplinary Collaboration on Cardiac Rehabilitation Outcomes in Patients With AMI
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT07045220
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 102
- Next
News
Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer
Phase 2 study demonstrates remarkable 93.3% objective response rate for lenvatinib plus tislelizumab in treating fumarate hydratase-deficient renal cell carcinoma, with 20% achieving complete response.